Analyst Expects This Drug Stock to Triple

BLU started trading on the Nasdaq on Sept. 5

Sep 30, 2019 at 11:44 AM
facebook twitter linkedin

Analysts are chiming in on Canadian clinical-stage biopharmaceutical firm BELLUS Health Inc (NASDAQ:BLU) today. Specifically, Jefferies initiated coverage with an "outperform" rating and a $20 price target -- a 208% premium to last night's close at $6.48.

Cowen followed suit with its own "outperform" rating, saying the company holds "blockbuster promise" in the chronic cough market, and called the shares undervalued. Guggenheim also weighed in, starting coverage with a "buy" rating and a $12 price target. All three brokerage firms served as lead underwriters on BLU's U.S. share offering, with the stock going public on the Nasdaq earlier this month.

Specifically, BLU stock opened at $7.50 on Sept. 5. The shares went on to slide all the way down to $6.22 by Sept. 27, and were last seen trading at $6.51 -- up 0.5% on the day, but stuck below their newly formed 10-day moving average.

blu stock daily price chart on sept 30


Special Offers from Schaeffer's Trading Partners